Analysis of factors influencing postprandial C-peptide levels in Japanese patients with type 2 diabetes: Comparison with C-peptide levels after glucagon load

Journal of Diabetes Investigation

Volumn 2, Issue 6, 2011, Pages 429-434

  Funakoshi, Shogo ^a   Fujimoto, Shimpei ^a   Hamasaki, Akihiro ^a   Fujiwara, Hideya ^a   Fujita, Yoshihito ^a   Ikeda, Kaori ^a   Takahara, Shiho ^a   Seino, Yutaka ^b   Inagaki, Nobuya ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

C peptide; HbA 1c; Meal load

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; INDEPENDENT VARIABLE; INSULIN RELEASE; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84859857952     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00126.x     Document Type: Article

References (27)

1. DeFronzo RA. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
2. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-1433.
3. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
4. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
5. Funakoshi S, Fujimoto S, Hamasaki A, et al. Analysis of factors influencing pancreatic β-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract 2008; 82: 353-358.
6. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual β-cell function in diabetes mellitus. Diabetes 1977; 26: 605-610.
7. Hendriksen C, Faber OK, Drejer J, et al. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia 1977; 13: 615-619.
8. Jayyab AK, Heding LG, Czyzyk A, et al. Serum C-peptide and IRI levels after administration of glucagon and glucose in non-insulin-dependent diabetics. Horm Metab Res 1982; 14: 112-116.
9. Gjessing HJ, Damsgaard EM, Matzen LE, et al. Reproducibility of β-cell function estimates in non-insulin-dependent diabetes mellitus. Diabetes Care 1987; 10: 558-562.
10. Funakoshi S, Fujimoto S, Hamasaki A, et al. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. J Diabetes Invest 2011. doi:.
11. Koskinen PJ, Viikari JS, Irjala KM. Glucagon-stimulated and postprandial plasma C-peptide values as measures of insulin secretory capacity. Diabetes Care 1988; 11: 318-322.
12. Aoki Y. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide. Diabetes Res Clin Pract 1991; 14: 165-173.
13. Aoki Y, Yanagisawa Y, Yazaki K, et al. Clinical significance of the two-hour postprandial serum C-peptide level in patients with diabetes mellitus. J Jpn Diabetes Soc 1992; 35: 811-818 (Japanese).
14. Chung JO, Cho DH, Chung DJ, et al. Plasma C-peptide level is inversely associated with family history of type 2 diabetes in Korean type 2 diabetic patients. Endocr J 2010; 57: 931-938.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62-S69.
16. Kajinuma H, Tanabashi S, Ishiwata K, et al. Urinary excretion of C-peptide in relation to renal function. In: Baba S (ed.). Proinsulin, Insulin, C-peptide. Excerpta Medica, Amsterdam, 1979; 183-189.
17. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
18. Japan Diabetes Society. (ed.). Treatment Guide for Diabetes 2007. Japan Diabetes Society, Bunkodo, Tokyo, Japan, 2007.
19. Seino Y, Ikeda M, Kurahachi H, et al. Failure of suppress plasma glucagon concentrations by orally administered glucose in diabetic patients after treatment. Diabetes 1978; 27: 1145-1150.
20. Kosaka K, Kuzuya T, Akanuma Y, et al. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980; 18: 23-28.
21. Iwasaki Y, Kondo K, Hasegawa H, et al. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test. Diabetes Res 1994; 25: 129-137.
22. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610-630.
23. Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007; 56: 1951-1959.
24. Højberg PV, Vilsbøll T, Zander M, et al. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes. Diabet Med 2008; 25: 1268-1275.
25. Fujimoto S, Nabe K, Takehiro M, et al. Impaired metabolism-secretion coupling in pancreatic β-cells: role of determinants of mitochondrial ATP production. Diabetes Res Clin Pract 2007; 77(Suppl. 1): S2-S10.
26. Mukai E, Fujimoto S, Sato H, et al. Exendin-4 suppresses Src activation and reactive oxygen species production in diabetic GK rat islets in an Epac-dependent manner. Diabetes 2011; 60: 218-226.
27. Meier JJ, Menge BA, Breuer TG, et al. Functional assessment of pancreatic β-cell area in humans. Diabetes 2009; 58: 1595-1603.